Table 2.
CRS, ICANS, treatment characteristics
| Characteristic | Anakinra dosing | p-value2 | ||
|---|---|---|---|---|
| Low, N = 151 | High, N = 281 | Total, N=43 | ||
| Peak CRS grade (ASTCT 2019) | 2 (1, 2) 1-3 | 2 (1, 2) 0-4 | 2 (1, 2) 0-4 | 0.4 |
| Peak ICANS grade (ASTCT 2019) | 4 (4, 4) 0-5 | 4 (3, 4) 0-4 | 4 (3, 4) 0-5 | 0.069 |
| Time to first anakinra administration (days) | 9 (8, 14) 6-41 | 8 (6, 11) 4-22 | 8 (7, 12) 4-41 | 0.13 |
| Corticosteroid treatment duration (days) | 13 (4, 24) 1-51 | 12 (8, 20) 3-43 | 12 (8, 21,5) 1-51 | >0.9 |
| Cumulative steroid dose (mg, dexamethasone equivalence) | 610 (395, 2,175) 25-8,000 | 562 (233, 945) 120-2,700 | 598 (260,1040) 25-8,000 | 0.3 |
| Cumulative dose of anakinra (mg) | 700 (450-1600) 100-12600 | 4200 (2600-5700) 400-18000 | 2800 (1125-4950) 100-18000 | 0.0001 |
| Duration of anakinra treatment (days) | 6 (4.5-10) 1-44 | 7.5 (4.75-12.2) 1-29 | 7 (4.5-11.5) 1-44 | 0.41 |
| Hospital location | ||||
| Spain | 11 (73%) | 7 (25%) | 18 (42%) | 0.004 |
| US | 4 (27%) | 21 (75%) | 25 (58%) | |
1
Median (IQR) Minimum-Maximum; n (%)
2
Wilcoxon rank sum test used for continuous variables; Fisher's exact test used for categorical variables;
Abbreviations: CRS, cytokine release syndrome; ICANS, Immune effector cell-associated neurotoxicity syndrome, LDH : lactate dehydrogenase, MD : missing data